Determinants of sub-optimal glycemic control among patients enrolled in a medicine dispensing programme in KwaZulu-Natal: A cohort study, 2018-2021.

Leigh C Johnston, Patrick Ngassa Piotie, Innocent Maposa, Sandhya Singh, Lazarus Kuonza, Alex De Voux
{"title":"Determinants of sub-optimal glycemic control among patients enrolled in a medicine dispensing programme in KwaZulu-Natal: A cohort study, 2018-2021.","authors":"Leigh C Johnston, Patrick Ngassa Piotie, Innocent Maposa, Sandhya Singh, Lazarus Kuonza, Alex De Voux","doi":"10.4102/phcfm.v16i1.4336","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong> The Central Chronic Medicines Dispensing and Distribution (CCMDD) programme facilitates clinically stable patients to collect their chronic medication from community-based pick-up points.</p><p><strong>Aim: </strong> We determined baseline glycaemic control and rates and predictors of becoming sub-optimally controlled for type 2 diabetes mellitus (T2DM) CCMDD-enrolled patients.</p><p><strong>Setting: </strong> The setting of the study was eThekwini, KwaZulu-Natal, South Africa.</p><p><strong>Methods: </strong> We performed a cohort study (April 2018- December 2021). We linked T2DM CCMDD-enrolled patients to glycated haemoglobin (HbA1c) data from the National Health Laboratory Service. We selected patients optimally controlled at their baseline HbA1c, with ≥ 1 repeat-test available. We used Kaplan-Meier analysis to assess survival rates and extended Cox regression to determine associations between time to sub-optimal control (HbA1c 7%) and predictors. Adjusted hazard ratios (aHRs), 95% confidence interval (CI), and p-values are reported.</p><p><strong>Results: </strong> Of the 41145 T2DM patients enrolled in the CCMDD programme, 7960 (19%) had a HbA1c result available. Twenty-seven percent (2147/7960) were optimally controlled at their baseline HbA1c. Of those controlled at baseline, 695 (32%) patients had a repeat test available, with 35% (242/695) changing to sub-optimal status. The HbA1c testing frequency as per national guidelines was associated with a lower hazard of sub-optimal glycaemic control (aHR: 0.46; 95% CI: 0.24-0.91; p-value = 0.024). Patients prescribed dual-therapy had a higher hazard of sub-optimal glycaemic control (aHR: 1.50; 95% CI: 1.16-1.95; p-value = 0.002) versus monotherapy.</p><p><strong>Conclusions: </strong> The HbA1c monitoring, in-line with testing frequency guidelines, is needed to alert the CCMDD programme of patients who become ineligible for enrolment. Patients receiving dual-therapy require special consideration.Contribution: Addressing identified shortfalls can assist programme implementation.</p>","PeriodicalId":47037,"journal":{"name":"African Journal of Primary Health Care & Family Medicine","volume":"16 1","pages":"e1-e12"},"PeriodicalIF":1.2000,"publicationDate":"2024-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11151363/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"African Journal of Primary Health Care & Family Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4102/phcfm.v16i1.4336","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PRIMARY HEALTH CARE","Score":null,"Total":0}
引用次数: 0

Abstract

Background:  The Central Chronic Medicines Dispensing and Distribution (CCMDD) programme facilitates clinically stable patients to collect their chronic medication from community-based pick-up points.

Aim:  We determined baseline glycaemic control and rates and predictors of becoming sub-optimally controlled for type 2 diabetes mellitus (T2DM) CCMDD-enrolled patients.

Setting:  The setting of the study was eThekwini, KwaZulu-Natal, South Africa.

Methods:  We performed a cohort study (April 2018- December 2021). We linked T2DM CCMDD-enrolled patients to glycated haemoglobin (HbA1c) data from the National Health Laboratory Service. We selected patients optimally controlled at their baseline HbA1c, with ≥ 1 repeat-test available. We used Kaplan-Meier analysis to assess survival rates and extended Cox regression to determine associations between time to sub-optimal control (HbA1c 7%) and predictors. Adjusted hazard ratios (aHRs), 95% confidence interval (CI), and p-values are reported.

Results:  Of the 41145 T2DM patients enrolled in the CCMDD programme, 7960 (19%) had a HbA1c result available. Twenty-seven percent (2147/7960) were optimally controlled at their baseline HbA1c. Of those controlled at baseline, 695 (32%) patients had a repeat test available, with 35% (242/695) changing to sub-optimal status. The HbA1c testing frequency as per national guidelines was associated with a lower hazard of sub-optimal glycaemic control (aHR: 0.46; 95% CI: 0.24-0.91; p-value = 0.024). Patients prescribed dual-therapy had a higher hazard of sub-optimal glycaemic control (aHR: 1.50; 95% CI: 1.16-1.95; p-value = 0.002) versus monotherapy.

Conclusions:  The HbA1c monitoring, in-line with testing frequency guidelines, is needed to alert the CCMDD programme of patients who become ineligible for enrolment. Patients receiving dual-therapy require special consideration.Contribution: Addressing identified shortfalls can assist programme implementation.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
夸祖鲁-纳塔尔省参加配药计划的患者血糖控制未达理想状态的决定因素:2018-2021 年队列研究。
背景: 中央慢性药物配发和分发(CCMDD)计划为临床病情稳定的患者从社区取药点领取慢性药物提供了便利。目的:我们确定了加入中央慢性药物配发和分发计划的 2 型糖尿病(T2DM)患者的血糖控制基线、血糖控制低于最佳水平的比例和预测因素: 研究地点:南非夸祖鲁-纳塔尔省的特克维尼: 我们进行了一项队列研究(2018 年 4 月至 2021 年 12 月)。我们将 T2DM CCMDD 注册患者与国家健康实验室服务的糖化血红蛋白(HbA1c)数据联系起来。我们选取了基线 HbA1c 得到最佳控制、重复检测次数≥ 1 次的患者。我们使用 Kaplan-Meier 分析法评估生存率,并使用扩展 Cox 回归法确定达到次优控制(HbA1c 7%)的时间与预测因素之间的关系。报告了调整后的危险比(aHRs)、95% 置信区间(CI)和 p 值: 在参加 CCMDD 计划的 41145 名 T2DM 患者中,7960 人(19%)有 HbA1c 结果。有 27% 的患者(2147/7960)的 HbA1c 基线得到了最佳控制。在基线 HbA1c 得到控制的患者中,有 695 人(32%)进行了重复检测,其中 35%(242/695)的患者转为次优状态。根据国家指南进行 HbA1c 检测的频率与血糖控制未达标的较低风险相关(aHR:0.46;95% CI:0.24-0.91;p 值 = 0.024)。与单一疗法相比,使用双重疗法的患者出现血糖控制不达标的风险更高(aHR:1.50;95% CI:1.16-1.95;p 值 = 0.002): 需要根据检测频率指南进行 HbA1c 监测,以提醒 CCMDD 计划注意不符合注册条件的患者。接受双重疗法的患者需要特别考虑:贡献:弥补发现的不足有助于计划的实施。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
3.30
自引率
10.00%
发文量
81
审稿时长
15 weeks
期刊最新文献
Home visits for preterm/low birthweight infants in South Africa: Qualitative evidence synthesis. Next steps for the East, Central and Southern Africa College of Family Physicians (ECSA-CFP). Prevalence and correlates of common mental disorders in people living with HIV in primary health care facilities in Ekurhuleni district. Perceptions of roles of community healthcare workers in early childhood in Limpopo, South Africa. Body composition estimates from bioelectrical impedance and its association with cardiovascular risk.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1